Mineralys Therapeutics (MLYS) Depreciation & Amortization (CF) (2024 - 2026)

Mineralys Therapeutics has reported Depreciation & Amortization (CF) for 3 years, with the latest figure at $6000.0 in Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 60.0% year-over-year to $6000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $50000.0 (changed 0.0% YoY) and the FY2025 annual result came in at $59000.0, up 37.21% from the prior year.
• Depreciation & Amortization (CF) eased to $6000.0 in Q1 2026 per MLYS's latest filing, from $13000.0 in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $16000.0 in Q2 2025 and troughed at $6000.0 in Q1 2026.
• A 3-year average of $12000.0 and a median of $13000.0 in 2025 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2025 and 2026: Depreciation & Amortization (CF) jumped 87.5% in 2025, then plunged 60.0% in 2026.
• Over 3 years, Depreciation & Amortization (CF) stood at $15000.0 in 2024, then declined by 13.33% to $13000.0 in 2025, then tumbled by 53.85% to $6000.0 in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $6000.0, $13000.0, and $15000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.